PMHNP Scope of Practice for General Psychiatry in California

If you’re a psychiatrist or psychiatric NP wondering whether you can legally prescribe Adderall, benzodiazepines, or buprenorphine over a video call — you’re not alone. The rules have changed more in the past five years than the previous twenty, and right now we’re in a holding pattern while federal regulators finalize permanent telehealth prescribing policies.

Here’s what you actually need to know to practice confidently and compliantly in 2026.

The Current Reality: Extended Flexibilities Through December 2026

Yes, you can prescribe Schedule II–V controlled substances via telehealth without an in-person exam — for now.

On January 2, 2026, the DEA and HHS announced their fourth extension of COVID-era telehealth flexibilities, keeping them in place through December 31, 2026. This means psychiatrists and PMHNPs can continue initiating treatment with stimulants, benzodiazepines, and other controlled medications after a proper telehealth evaluation, just as they’ve been doing since March 2020.

The catch? These are temporary rules. The DEA is working on permanent regulations that will likely require additional compliance steps — possibly including special telemedicine registrations, periodic in-person visits for certain medications, or stricter documentation requirements.

What this means for your practice:

• You can evaluate new patients via video and prescribe controlled substances if clinically appropriate
• Document thoroughly — your telehealth exam should be as comprehensive as an in-person visit
• Use two-way audio-visual technology (video calls), not just phone, for initial controlled substance prescriptions
• Stay current on proposed DEA rules, which could change requirements by late 2026

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

The DEA’s Proposed Permanent Rules: What’s Coming

In January 2025, the DEA proposed three new rules to replace temporary COVID policies. These aren’t final yet, but they signal where regulations are headed:

1. Special Telemedicine Registration for Schedule II Prescribing

The DEA plans to create a ‘Special Telemedicine Prescriber Registration’ that would allow qualified providers to prescribe controlled substances to new patients via telehealth without any in-person exam. For Schedule II medications (stimulants, certain opioids), this registration would initially be limited to:

• Board-certified psychiatrists
• Hospice/palliative care physicians
• Long-term care facility physicians
• Pediatricians (for specific indications)

This is significant: it means psychiatrists could maintain a fully virtual practice prescribing ADHD medications or other Schedule II drugs, provided they obtain this special registration. The details — application requirements, ongoing reporting obligations, fees — are still being worked out through public comment.

2. Buprenorphine Flexibility for OUD Treatment

For addiction psychiatrists, the proposed rule would allow prescribing buprenorphine for opioid use disorder via telehealth (including audio-only calls) for up to six months before requiring an in-person visit. This acknowledges that medication-assisted treatment often works better when patients can access care immediately, without travel barriers.

3. Platform Registration and National PDMP

Online telehealth platforms will be required to register with the DEA for the first time, and a national Prescription Drug Monitoring Program would integrate state PDMP data. This addresses concerns about over-prescribing and ‘doctor shopping’ across state lines.

Bottom line: Prepare for more administrative steps in 2026–2027, but also expect clearer, more permanent pathways for legitimate telepsychiatry practice.

State Laws Add Another Layer of Complexity

Federal DEA rules set the floor, but states can impose stricter requirements. Here’s where it gets messy: telehealth prescribing laws vary dramatically by state.

Florida: Psychiatric Carve-Out

Florida explicitly permits Schedule II prescribing via telehealth for psychiatric treatment — meaning you can prescribe Adderall for ADHD via video, but not the same medication for another indication. The law prohibits most Schedule II telehealth prescribing except for:

• Psychiatric disorders
• Inpatient hospital care
• Hospice
• Nursing home residents

Florida also allows out-of-state providers to register for telehealth practice without a full Florida license, though you must still follow Florida’s rules (including mandatory PDMP checks and e-prescribing).

Texas: NPs Can’t Prescribe Schedule II (Except in Hospitals)

Texas psychiatric NPs face a hard stop: they cannot prescribe Schedule II controlled substances in outpatient settings. Period. This means a Texas PMHNP cannot write for Adderall, even via telehealth. Schedule II prescribing authority for NPs is limited to hospital inpatient care (24+ hour admissions) or hospice.

If you’re operating a telehealth service in Texas, you need psychiatrists (MDs/DOs) on staff to handle stimulant prescriptions, or patients must see a physician for those medications.

California: PDMP Checks Every 4 Months

California has no special telehealth restrictions on controlled substances, but requires prescribers to check the CURES database before first prescribing Schedule II–IV drugs and every four months thereafter if treatment continues. Miss that quarterly check and you’re out of compliance.

California also mandates 100% e-prescribing for all prescriptions (with rare exceptions).

New York: Mandatory PMP Check Every Time

New York requires checking the state Prescription Monitoring Program before every Schedule II, III, or IV prescription — not just the first one. New York also mandates e-prescribing for all prescriptions (controlled and non-controlled) and has some of the nation’s strictest opioid prescribing laws.

The upside: New York now allows experienced psychiatric NPs (3,600+ practice hours) to practice independently, prescribing controlled substances without physician oversight.

The Licensing Requirement You Can’t Avoid

Every state requires you to be licensed where your patient is located during the telehealth visit. You can’t practice ‘license-free’ via telehealth. If your patients are in five states, you need five state medical licenses (or nursing licenses for NPs).

Some states participate in the Interstate Medical Licensure Compact (IMLC), which streamlines the multi-state licensing process for physicians. Texas, Illinois, and Pennsylvania are IMLC members; California joined in 2022. New York and Florida are not in the compact, so licensing there takes longer.

Psychiatrist vs. PMHNP: Who Can Prescribe What?

Psychiatrists (MD/DO) have full independent prescribing authority in all states. If you’re a board-certified psychiatrist with a state medical license and DEA registration, you can prescribe any controlled substance within your scope of practice, whether in-person or via telehealth (subject to the federal and state rules above).

Psychiatric Mental Health Nurse Practitioners face state-by-state scope of practice variations:

If you’re a PMHNP joining a telehealth platform, understand your state’s rules. In full-practice states like New York, you can operate independently. In restricted states like Texas or Florida, you’ll need a collaborating physician arrangement.

The Economics: Why Platforms Make Sense vs. DIY Marketing

Let’s talk about something nobody discusses openly: the real cost of acquiring psychiatric patients.

Many providers consider DIY marketing — Google Ads, SEO, Psychology Today listings — to avoid ‘paying a platform fee.’ Here’s the reality those channels don’t advertise:

DIY Patient Acquisition Costs:

• Google Ads for mental health keywords: $15–40+ per click; most clicks don’t convert to booked appointments
• Realistic cost per booked patient through PPC: $200–400+ (factoring in click costs, no-shows, and qualification time)
• SEO investment: 6–12 months of consistent content, backlink building, and technical optimization before meaningful patient flow — often $2,000–4,000/month in agency fees
• Psychology Today Premium Listing: $40–60/month, but you’re competing with hundreds of other providers on the same search results page
• Zocdoc or similar directories: $200–400/month subscription plus $35–100 per booking fee

Add it up: if you’re spending $3,000–5,000 per month on marketing with uncertain results, you’re gambling. Some months you get 10 qualified leads. Other months you get three tire-kickers who ghost after the first call.

Platform Model (Like Klarity Health):

Pay only when a qualified patient books with you. No upfront marketing spend, no monthly subscriptions, no wasted ad budget. The platform handles:

• Patient acquisition and vetting (pre-qualified, matched to your specialty)
• Telehealth infrastructure (no separate platform fees)
• Insurance credentialing and billing (for insurance panels)
• Scheduling and no-show management

You pay a standard fee per new patient lead — only when you see patients. That’s guaranteed ROI vs. the uncertainty of building your own patient pipeline from scratch.

This model works especially well for providers who:

• Are starting out or scaling up (don’t have months to wait for SEO)
• Want to avoid the complexity of managing marketing agencies and ad spend
• Prefer predictable economics (pay per patient, not per click or per month)
• Need both insurance and cash-pay patient flow

For established providers with existing marketing infrastructure, DIY channels can eventually be cost-effective — if you have the budget, expertise, and patience. But for most psychiatrists and PMHNPs, especially those juggling full patient panels already, removing patient acquisition risk entirely is worth the per-appointment fee.

Compliance Checklist: Practicing Safely in 2026

Whether you’re on a platform or building your own practice, here’s what you need to stay compliant:

Federal Requirements

• DEA Registration: Current DEA license in each state where you prescribe
• MATE Act Training: 8-hour training on substance use disorder and pain management (one-time requirement for DEA registration/renewal since 2023)
• Two-Way Video: Use interactive audio-visual technology for initial controlled substance prescriptions (not phone-only, except for buprenorphine OUD treatment)
• Documentation: Comprehensive evaluation notes — history, mental status exam, clinical rationale for medication choice

State-Specific Requirements

• PDMP Checks: Query state prescription monitoring database before prescribing (requirements vary: CA every 4 months; NY every time; TX for opioids/benzos)
• E-Prescribing: Virtually all states mandate electronic prescribing for controlled substances
• State Licensure: Full medical or nursing license in the state where your patient is located
• Collaborative Agreements: If you’re an NP in a restricted-practice state (Texas, Florida, Pennsylvania), ensure your physician collaboration agreement is current and covers telehealth

Platform-Specific

• HIPAA Compliance: Use secure, encrypted telehealth platforms
• Malpractice Insurance: Verify coverage extends to telehealth and all states where you practice
• Informed Consent: Document patient consent for telehealth services (some states explicitly require this)

What to Watch in 2026

The regulatory landscape will continue evolving:

1. DEA Final Rules: Expected by late 2026. Watch for finalization of the Special Telemedicine Registration and buprenorphine flexibilities.

2. State Telehealth Laws: Several states are considering legislation to expand or restrict telehealth prescribing. Pennsylvania may finally pass comprehensive telehealth legislation; other states may follow Florida’s psychiatric carve-out model.

3. Interstate Licensure Expansion: More states joining the IMLC or creating multi-state agreements could simplify licensing for multi-state telehealth practices.

4. Platform Registration: If the DEA’s proposed platform registration rule is finalized, telehealth companies will need to register federally and implement additional compliance measures (which should increase patient safety and platform legitimacy).

The Bottom Line

Can you prescribe controlled substances via telehealth? Yes — safely, legally, and profitably, if you know the rules.

Current status (through Dec 2026): Full federal flexibility for prescribing Schedule II–V medications via telehealth after proper evaluation.

Future outlook: More structured but still feasible. Board-certified psychiatrists will likely have clear pathways to prescribe Schedule II drugs via telehealth indefinitely through special registration.

State laws: The real compliance challenge. You must know your state’s PDMP rules, NP scope of practice limits, and any telehealth-specific restrictions.

Economic reality: Building a patient pipeline from scratch is expensive and slow. Platforms that handle patient acquisition remove the financial risk and let you focus on clinical care — which is why many experienced providers choose that model even after trying DIY marketing.

If you’re ready to expand your practice via telehealth without gambling on marketing channels or navigating compliance solo, explore how Klarity Health connects psychiatrists and PMHNPs with pre-qualified patients — with built-in compliance support, transparent economics, and no upfront marketing spend.

Frequently Asked Questions

Can I prescribe Adderall via telehealth to a new patient I’ve never met in person?

Yes, under current federal rules (extended through December 2026). You must conduct a thorough evaluation via two-way video, document appropriately, and ensure the prescription is for a legitimate medical purpose. Some states (like Florida) explicitly allow this for psychiatric treatment; others defer to federal law.

What happens when the federal telehealth flexibilities expire at the end of 2026?

The DEA is expected to finalize permanent rules before then. Psychiatrists will likely be able to obtain a Special Telemedicine Registration to continue prescribing Schedule II drugs via telehealth without in-person exams. Watch for updates in late 2026.

Do I need a separate DEA registration for each state where I prescribe via telehealth?

Yes. You need a DEA registration (with an address) in each state where you prescribe controlled substances to patients. Most telehealth prescribers maintain multiple state DEA registrations.

Can psychiatric nurse practitioners prescribe controlled substances via telehealth independently?

It depends on the state. In full-practice states like New York (after 3,600 hours) and California (transitioning), yes. In restricted states like Texas and Florida, NPs need physician supervision and may face limits on Schedule II prescribing.

What’s the difference between audio-only and audio-visual telehealth for prescribing?

Federal rules require two-way audio-visual (video) for most controlled substance prescribing via telehealth. Audio-only (telephone) is currently allowed only for buprenorphine prescribing for opioid use disorder. State laws may vary, but video is the safer standard for psychiatric medication management.

Do I have to check the state PDMP before every controlled substance prescription?

It depends on state law. New York requires checking before every Schedule II–IV prescription. California requires an initial check and then every four months. Texas requires checks for opioids and benzodiazepines. Check your specific state’s requirements.

Can I use an out-of-state medical license to prescribe via telehealth?

No. You must be licensed in the state where your patient is physically located during the telehealth visit. Some states (like Florida) offer special telehealth registrations for out-of-state providers, but you still must follow that state’s rules.

Is it legal to prescribe benzodiazepines for anxiety via telehealth long-term?

Yes, under current federal rules, as long as you’re following the standard of care (regular evaluations, monitoring for misuse, checking PDMP). State laws don’t specifically prohibit this, though some states have extra requirements for ongoing controlled substance prescriptions (documentation, periodic in-person visits, etc.).

Citations

1. U.S. Department of Health & Human Services (HHS). ‘HHS and DEA Extend Telemedicine Flexibilities for Prescribing Controlled Medications Through 2026.’ Press release, January 2, 2026. https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html

2. U.S. Drug Enforcement Administration (DEA). ‘DEA Announces Three New Telemedicine Rules to Continue Open Access to Care While Establishing New Patient Protections.’ Press release, January 16, 2025. https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access

3. Akerman LLP. ‘Harmonizing Federal and Florida Laws on Prescribing Controlled Substances Through Telehealth.’ Legal bulletin, March 2023. https://www.akerman.com/en/perspectives/hrx-harmonizing-federal-and-florida-laws-on-prescribing-controlled-substances-through-telehealth.html

4. Texas Medical Board. ‘Prescriptive Authority and Supervision FAQ.’ Updated 2024. https://www.tmb.texas.gov/resources/for-applicants-and-licensees/prescribing-and-supervision

5. Tebra (The Intake). ‘State-by-State Breakdown of Nurse Practitioner Practice Authority Laws.’ Updated December 4, 2025. https://www.tebra.com/theintake/checklists-and-guides/legal-and-compliance/nurse-practitioner-laws-by-state

Source:

• https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html#:~:text=WASHINGTON%E2%80%94JANUARY%202%2C%202026%E2%80%94The%20U,while%20permanent%20rules%20are%20finalized
• https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html#:~:text=announced%20a%20fourth%20temporary%20extension,while%20permanent%20rules%20are%20finalized
• https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access#:~:text=Expansion%20of%20Buprenorphine%20Treatment%20via,Telemedicine%20Encounter
• https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access#:~:text=registration%20is%20available%20to%20medical,V%20medications
• https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access#:~:text=For%20the%20first%20time%20online,being%20of%20patients
• https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access#:~:text=In%20developing%20these%20rules%2C%20DEA,person%20by%20the%20medical%20provider
• https://www.akerman.com/en/perspectives/hrx-harmonizing-federal-and-florida-laws-on-prescribing-controlled-substances-through-telehealth.html#:~:text=telehealth%20to%20prescribe%20schedules%20III,one%20of%20the%20following%20categories
• https://www.jdsupra.com/legalnews/states-and-feds-signal-big-changes-to-9301791/#:~:text=of%20Ohio%E2%80%99s%20new%20telehealth%20prescribing,substance%20use%20disorder%20treatment%2C%20is
• https://www.akerman.com/en/perspectives/hrx-harmonizing-federal-and-florida-laws-on-prescribing-controlled-substances-through-telehealth.html#:~:text=No%20special%20registration%20is%20required,the%20State%20to%20do%20so
• https://www.tebra.com/theintake/checklists-and-guides/legal-and-compliance/nurse-practitioner-laws-by-state#:~:text=,start%20their%20own%20medical%20practices